JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB55271

Anti-IDH2 antibody [5F11]

Be the first to review this product! Submit a review

|

(48 Publications)

Mouse Monoclonal IDH2 antibody. Suitable for Flow Cyt, WB, IHC-P, ICC/IF and reacts with Human, Recombinant fragment - Human samples. Cited in 48 publications. Immunogen corresponding to Recombinant Fragment Protein within Human IDH2 aa 350-500.

View Alternative Names

IDH, ICD-M, IDP, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase, IDH2

8 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IDH2 antibody [5F11] (AB55271)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IDH2 antibody [5F11] (AB55271)

IDH2 antibody (ab55271) used in immunohistochemistry at 3ug/ml on formalin fixed and paraffin embedded human colon.

This image was generated using the ascites version of the product.

Flow Cytometry - Anti-IDH2 antibody [5F11] (AB55271)
  • Flow Cyt

Unknown

Flow Cytometry - Anti-IDH2 antibody [5F11] (AB55271)

Overlay histogram showing MCF7 cells stained with ab55271 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab55271, 1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2μg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in MCF7 cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.

This image was generated using the ascites version of the product.

Immunocytochemistry/ Immunofluorescence - Anti-IDH2 antibody [5F11] (AB55271)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-IDH2 antibody [5F11] (AB55271)

ICC/IF image of ab55271 stained Mcf7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab55271, 10μg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43μM.

This image was generated using the ascites version of the product.

Western blot - Anti-IDH2 antibody [5F11] (AB55271)
  • WB

Lab

Western blot - Anti-IDH2 antibody [5F11] (AB55271)

False colour image of Western blot : Anti-IDH2 antibody [5F11] staining at 1/1000 dilution, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab55271 was shown to bind specifically to IDH2. A band was observed at 48 kDa in wild-type Jurkat cell lysates with no signal observed at this size in IDH2 knockout cell line ab282331 (knockout cell lysate ab283148). To generate this image, wild-type and IDH2 knockout Jurkat cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) at 1/20000 dilution.

All lanes:

Western blot - Anti-IDH2 antibody [5F11] (ab55271) at 1/1000 dilution

Lane 1:

Wild-type Jurkat cell lysate at 20 µg

Lane 2:

IDH2 knockout Jurkat cell lysate at 20 µg

Lane 2:

Western blot - Human IDH2 knockout Jurkat cell line (<a href='/en-us/products/cell-lines/human-idh2-knockout-jurkat-cell-line-ab282331'>ab282331</a>)

Lane 3:

MOLT-4 cell lysate at 20 µg

Lane 4:

HEK-293 cell lysate at 20 µg

Predicted band size: 50 kDa

Observed band size: 48 kDa

false

Western blot - Anti-IDH2 antibody [5F11] (AB55271)
  • WB

Lab

Western blot - Anti-IDH2 antibody [5F11] (AB55271)

Western blot : Anti-IDH2 antibody [5F11] (ab55271) staining at 1/1000 dilution, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in magenta. In Western blot, ab55271 was shown to bind specifically to IDH2. A band was observed at 51 kDa in wild-type A549 cell lysates with no signal observed at this size in IDH2 knockout cell line. To generate this image, wild-type and IDH2 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L 800CW and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-IDH2 antibody [5F11] (ab55271) at 1/1000 dilution

Lane 1:

Wild-type A549 cell lysate at 20 µg

Lane 2:

IDH2 knockout A549 cell lysate at 20 µg

Lane 3:

Wild-type Jurkat cell lysate at 20 µg

Lane 4:

IDH2 knockout Jurkat <a href='/en-us/products/cell-lines/human-idh2-knockout-jurkat-cell-line-ab282331'>ab282331</a> cell lysate at 20 µg

Secondary

All lanes:

Goat anti-Mouse IgG H&L 800CW and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution

Observed band size: 51 kDa

false

Western blot - Anti-IDH2 antibody [5F11] (AB55271)
  • WB

Unknown

Western blot - Anti-IDH2 antibody [5F11] (AB55271)

Western blot against tagged recombinant protein immunogen using ab55271 IDH2 antibody at 1ug/ml. Predicted band size of immunogen is 37 kDa

This image was generated using the ascites version of the product.

All lanes:

Western blot - Anti-IDH2 antibody [5F11] (ab55271)

Predicted band size: 50 kDa

false

Western blot - Anti-IDH2 antibody [5F11] (AB55271)
  • WB

Unknown

Western blot - Anti-IDH2 antibody [5F11] (AB55271)

The blocking agent used is 5% milk.

This image was generated using the ascites version of the product.

All lanes:

Western blot - Anti-IDH2 antibody [5F11] (ab55271)

Lane 1:

IDH2 in transfected 293T cell line

Lane 2:

Non-transfected lysate

Predicted band size: 50 kDa

false

Western blot - Anti-IDH2 antibody [5F11] (AB55271)
  • WB

CiteAb

Western blot - Anti-IDH2 antibody [5F11] (AB55271)

Western Blotting using Anti-IDH2 antibody [5F11], ab55271. Publication image from Lee, W. D. et al., 2019, Nat Commun, 30903027. Legend direct from paper.

A quantitative view of mitochondrial and cytosolic fluxes in the TCA cycle and citrate metabolism under normoxia. a–d Mass-isotopomer labeling kinetics of citrate in mitochondria (a) and cytosol (b), and malate in mitochondria (c) and cytosol (d) when feeding HeLa cells with [U-13C]-glutamine under standard normoxic conditions. e Measured isotopic labeling ratio in HeLa cells for citrate m + 5 /m + 4 and malate m + 3 /m + 4 in media (red) in comparison to the expected labeling via computational simulation, considering the measured labeling kinetics of citrate and malate in mitochondria (green) and cytosol (orange). f Gibbs free energy of mitochondrial (IDH2/3) and cytosolic (IDH1) IDH isozymes (in the oxidative direction) in HeLa cells under normoxia (green) and hypoxia (red). g Mitochondrial and cytosolic fluxes, showing percentage from citrate synthase flux (which is 0.48 mM h−1). Arrow represents the direction of net flux; number represents net flux in the direction of the arrow and number in parenthesis correspond to the backward flux. Confidence intervals for estimated fluxes are shown in Supplementary Data 8. h The measured mass-isotopomer distribution of palmitate when feeding cells with [U-13C]-glutamine (green) is consistent with the simulated fit (orange). For the simulation, acetyl-CoA labeling was assumed to follow a binomial distribution with a probability of 7.1% having m + 2 labeling form. i Validation of the method based on knock-down of IDH1 or IDH2 genes and following citrate isotopic labeling after feeding cells with [U-13C]-glutamine. Upon IDH1 knockdown, the ratios between citrate m + 5 and m + 4 in mitochondria and cytosol are similar, indicating that all reductive glutamine flux occurred in mitochondria (where citrate m + 4 is produced from malate m + 4). Meanwhile, IDH2 knockdown resulted in a higher citrate m + 5 to m + 4 ratio in cytosol, indicating that reductive IDH1 remains active. n.s. not significant. *P < 0.05 and **P < 0.01 by two-sample t-test. Data are mean ± SD, n = 3 independent biological replicates

false

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

5F11

Isotype

IgG1

Light chain type

kappa

Carrier free

No

Reacts with

Human

Applications

ICC/IF, WB, IHC-P, Flow Cyt

applications

Immunogen

Recombinant Fragment Protein within Human IDH2 aa 350-500. The exact immunogen used to generate this antibody is proprietary information.

P48735

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/mouse-igg1-kappa-monoclonal-15-6e10a7-isotype-control-ab170190'>ab170190</a> - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.</p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p>This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.</p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>" }, "Recombinant fragment - Human": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p>This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.</p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Product details

This product was changed from ascites to tissue culture supernatant on 13th Feb 2019. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.

Properties and storage information

Form
Liquid
Purity
Tissue culture supernatant
Storage buffer
pH: 7.4
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Isocitrate dehydrogenase 2 (IDH2) is an enzyme that converts isocitrate to alpha-ketoglutarate in the citric acid cycle through oxidative decarboxylation. IDH2 also known as NADP-dependent isocitrate dehydrogenase has a molecular weight of about 51 kDa. This protein expresses in the mitochondria serving an important role in cellular energy production and intermediary metabolism. By facilitating this conversion IDH2 impacts cellular respiration and energy balance.
Biological function summary

The IDH2 enzyme facilitates cellular metabolism by producing NADPH critical for biosynthesis and antioxidant defense. It functions within the oxidative decarboxylation of isocitrate providing reducing equivalents to keep cellular redox balance. Although not part of a larger enzymatic complex IDH2 acts synergistically with other metabolic enzymes to maintain cellular biochemical pathways.

Pathways

The IDH2 protein participates in the citric acid cycle and redox homeostasis. IDH2 contributes to the tricarboxylic acid (TCA) pathway coupling with other TCA components such as citrate synthase and aconitase. Within the redox pathway it influences glucose metabolism via its link with enzymes like NADPH oxidase ensuring a steady supply of NADPH for biosynthetic reactions.

The IDH2 protein links to certain cancers like acute myeloid leukemia (AML) due to mutations such as IDH2 R140Q and IDH2 R172K which lead to the production of oncometabolite 2-hydroxyglutarate. This oncometabolite influences epigenetic regulation and cellular differentiation. IDH2 mutations often associate with altered tumor suppressor pathways involving proteins like TP53 contributing to tumorigenesis and impaired cellular differentiation.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Plays a role in intermediary metabolism and energy production (PubMed : 19228619, PubMed : 22416140). It may tightly associate or interact with the pyruvate dehydrogenase complex (PubMed : 19228619, PubMed : 22416140).
See full target information IDH2

Publications (48)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 15:3445 PubMed38658533

2024

Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Jiang-Jiang Li,Tiantian Yu,Peiting Zeng,Jingyu Tian,Panpan Liu,Shuang Qiao,Shijun Wen,Yumin Hu,Qiao Liu,Wenhua Lu,Hui Zhang,Peng Huang

Biomedicines 11: PubMed36831011

2023

Targeting Mitochondrial IDH2 Enhances Antitumor Activity of Cisplatin in Lung Cancer via ROS-Mediated Mechanism.

Applications

Unspecified application

Species

Unspecified reactive species

He Li,Jiang-Jiang Li,Wenhua Lu,Jing Yang,Yunfei Xia,Peng Huang

The EMBO journal 42:e110620 PubMed36637036

2023

IDH2 stabilizes HIF-1α-induced metabolic reprogramming and promotes chemoresistance in urothelial cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Keisuke Shigeta,Masanori Hasegawa,Takako Hishiki,Yoshiko Naito,Yuto Baba,Shuji Mikami,Kazuhiro Matsumoto,Ryuichi Mizuno,Akira Miyajima,Eiji Kikuchi,Hideyuki Saya,Takeo Kosaka,Mototsugu Oya

Journal of biochemical and molecular toxicology 37:e23289 PubMed36536497

2022

Proteomics analysis of meclofenamic acid-treated small cell lung carcinoma cells revealed changes in cellular energy metabolism for cancer cell survival.

Applications

Unspecified application

Species

Unspecified reactive species

Sevinc Yanar,Murat Kasap,Aylin Kanli,Gurler Akpinar,Mehmet Sarihan

Science advances 8:eabp8293 PubMed36525494

2022

In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Akash K Kaushik,Amy Tarangelo,Lindsey K Boroughs,Mukundan Ragavan,Yuanyuan Zhang,Cheng-Yang Wu,Xiangyi Li,Kristen Ahumada,Jui-Chung Chiang,Vanina T Tcheuyap,Faeze Saatchi,Quyen N Do,Cissy Yong,Tracy Rosales,Christina Stevens,Aparna D Rao,Brandon Faubert,Panayotis Pachnis,Lauren G Zacharias,Hieu Vu,Feng Cai,Thomas P Mathews,Giannicola Genovese,Barbara S Slusher,Payal Kapur,Xiankai Sun,Matthew Merritt,James Brugarolas,Ralph J DeBerardinis

Cancer discovery 13:170-193 PubMed36222845

2022

Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.

Applications

Unspecified application

Species

Unspecified reactive species

Junhua Lyu,Yuxuan Liu,Lihu Gong,Mingyi Chen,Yazan F Madanat,Yuannyu Zhang,Feng Cai,Zhimin Gu,Hui Cao,Pranita Kaphle,Yoon Jung Kim,Fatma N Kalkan,Helen Stephens,Kathryn E Dickerson,Min Ni,Weina Chen,Prapti Patel,Alice S Mims,Uma Borate,Amy Burd,Sheng F Cai,C Cameron Yin,M James You,Stephen S Chung,Robert H Collins,Ralph J DeBerardinis,Xin Liu,Jian Xu

iScience 25:104823 PubMed35992092

2022

Targeting HOTAIRM1 ameliorates glioblastoma by disrupting mitochondrial oxidative phosphorylation and serine metabolism.

Applications

Unspecified application

Species

Unspecified reactive species

Wei Han,Shanshan Wang,Yingjiao Qi,Fan Wu,Ningyu Tian,Boqin Qiang,Xiaozhong Peng

Leukemia 36:1150-1159 PubMed34997181

2022

MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylases.

Applications

Unspecified application

Species

Unspecified reactive species

An-Ping Lin,Zhijun Qiu,Purushoth Ethiraj,Binu Sasi,Carine Jaafar,Dinesh Rakheja,Ricardo C T Aguiar

eLife 10: PubMed34874009

2021

Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer Biology.

Applications

Unspecified application

Species

Unspecified reactive species

Timothy M Errington,Alexandria Denis,Anne B Allison,Renee Araiza,Pedro Aza-Blanc,Lynette R Bower,Jessica Campos,Heidi Chu,Sarah Denson,Cristine Donham,Kaitlyn Harr,Babette Haven,Elizabeth Iorns,Jennie Kwok,Elysia McDonald,Steven Pelech,Nicole Perfito,Amanda Pike,Darryl Sampey,Michael Settles,David A Scott,Vidhu Sharma,Todd Tolentino,Angela Trinh,Rachel Tsui,Brandon Willis,Joshua Wood,Lisa Young

Cancers 13: PubMed34680392

2021

Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations.

Applications

Unspecified application

Species

Unspecified reactive species

Marie Sabatier,Emeline Boet,Sonia Zaghdoudi,Nathan Guiraud,Alexis Hucteau,Nathaniel Polley,Guillaume Cognet,Estelle Saland,Laura Lauture,Thomas Farge,Ambrine Sahal,Vera Pancaldi,Emeline Chu-Van,Florence Castelli,Sarah Bertoli,Pierre Bories,Christian Récher,Héléna Boutzen,Véronique Mansat-De Mas,Lucille Stuani,Jean-Emmanuel Sarry
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com